Comparable stake leader
Frazier Life Sciences Public Fund, L.P.
SEC ownership of Phathom Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001783183.
Disclosed value leader
Frazier Life Sciences Management, L.P.
Comparable rows
4/50
Latest evidence
30 Jun 2026
- Public ticker
- PHAT on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Frazier Life Sciences Public Fund, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Frazier Life Sciences Public Fund, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001783183
- Issuer location
- Florham Park, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Phathom Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Frazier Life Sciences Pub...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
4/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 8.6%
46 rows are not safely comparable across share classes.
13D/G row: Frazier Life Sciences Public Fund, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Frazier Life Sciences Public Fund, L.P. leads the comparable SEC ownership view at 8.6%.
4 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Frazier Life Sciences Public Fund, L.P.'s linked filing trail.
Comparable ownership
Top 4
Frazier Life Sciences Public Fund...
8.6%
BlackRock, Inc.
5.5%
Carlyle Group Inc.
4.9%
MILLENNIUM MANAGEMENT LLC
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. |
13D/G
James N. Topper
|
8.6%
Reported 13D/G
· 01 Nov 2025
|
$70,447,299
5,985,327 shares
|
$0 | 01 Nov 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.5%
Reported 13D/G
· 30 Jun 2026
|
$49,097,648
4,525,129 shares
|
— | 30 Jun 2026 |
| Carlyle Group Inc. |
13F
13D/G
Company
|
4.9%
Reported 13D/G
· 28 Aug 2025
|
$37,940,367
3,496,808 shares
|
— | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
Company
|
4.2%
Reported 13D/G
· 30 Jun 2026
|
$36,627,799
3,375,834 shares
|
— | 30 Jun 2026 |
| Medicxi Ventures Management (Jersey) Ltd |
13F
3/4/5
Company · 10%+ Owner
|
—
denominator unverified
|
$80,990,606
7,464,572 shares
|
— | 30 Jun 2026 |
| James N. Topper |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$66,187,256
5,974,949 shares
mixed-class rows
|
— | 19 May 2026 |
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$30,420,222
3,755,583 shares
|
— | 24 Jan 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
—
denominator unverified
|
$135,261,406
12,466,489 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$7,079.
Buys
$0
Insiders: 0
Sells
$7,079
Insiders: 1
Net
-$7,079
Shares: -524
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 524
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 524 | $0 | $7,079 | -$7,079 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Phathom Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
James N. Topper
Net 12M change
-$7,079
Latest report
06 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James N. Topper | Director, 10%+ Owner | $66,187,256 | Mixed | 19 May 2026 | ||
| Medicxi Ventures Management (Jersey) Ltd | 10%+ Owner | $60,463,034 | Mixed | 24 Jan 2024 | ||
| TAKEDA PHARMACEUTICAL CO LTD | 10%+ Owner | $30,420,222 | Filing P/S | 24 Jan 2024 | ||
| David A. Socks | Director | $11,216,740 | Mixed | 23 May 2024 | ||
| Azmi Nabulsi | Chief Operating Officer | $10,029,637 | Mixed | 27 Feb 2025 | ||
| Steven L. Basta | President and CEO, Director | $4,785,898 | Mixed | 10 Feb 2026 | ||
| Terrie Curran | President and Chief Executive, Director | $2,399,933 | Mixed | 27 Feb 2025 | ||
| Asit Parikh | Director | $1,917,830 | Mixed | 22 May 2026 | ||
| Sanjeev Narula | Chief Financial & Bus. Officer | $1,575,638 | Median | 06 Oct 2026 | ||
| Molly Henderson | CFO and CBO | $1,558,384 | Mixed | 07 Apr 2025 | ||
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | $1,136,621 | Mixed | 10 Feb 2026 | ||
| Frank Karbe | Director | $1,017,920 | Mixed | 19 May 2026 | ||
| Robert Charles Breedlove | Principal Accounting Officer | $734,075 | -$7,079 | -0.96% | Mixed | 03 Sep 2026 |
| Michael F. Cola | Director | $710,151 | Mixed | 19 May 2026 | ||
| Heidi Fields | Director | $601,295 | Mixed | 19 May 2026 | ||
| Mark Stenhouse | Director | $601,295 | Mixed | 19 May 2026 | ||
| Theodore R. Schroeder | Director | $501,305 | Mixed | 19 May 2026 | ||
| Anthony J. Guzzo | VP, Chief Accounting Officer | $71,787 | Mixed | 19 Jan 2022 | ||
| Tadataka Yamada | Director | Mixed | 21 May 2021 |
Recent insider transactions for Phathom Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sanjeev Narula | PHAT | Common Stock | Tax liability | -5.91% | -13,485 | 214,718 | 06 Oct 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -0.77% | -460 | 59,465 | 03 Sep 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -2.53% | -1,555 | 59,925 | 14 Jul 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Gift | 23.2% | 28,000 | 148,500 | 22 May 2026 | by Trust | ||
| Asit Parikh | PHAT | Common Stock | Gift | -53.7% | -28,000 | 24,122 | 22 May 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Options Exercise | 50.6% | 17,500 | 52,122 | 20 May 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock (Right to Buy) | Disposed to Issuer | -100% | -17,500 | 0 | 20 May 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Award | 229.7% | 24,122 | 34,622 | 19 May 2026 | Direct | ||
| James N. Topper | PHAT | Common Stock | Award | 56.6% | 24,122 | 66,718 | 19 May 2026 | Direct | ||
| Mark Stenhouse | PHAT | Common Stock | Award | 80.4% | 24,122 | 54,122 | 19 May 2026 | Direct | ||
| Heidi Fields | PHAT | Common Stock | Award | 80.4% | 24,122 | 54,122 | 19 May 2026 | Direct | ||
| Michael F. Cola | PHAT | Common Stock | Award | 60.6% | 24,122 | 63,920 | 19 May 2026 | Direct | ||
| Frank Karbe | PHAT | Common Stock | Award | 35.7% | 24,122 | 91,622 | 19 May 2026 | Direct | ||
| Theodore R. Schroeder | PHAT | Common Stock | Award | 114.9% | 24,122 | 45,122 | 19 May 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Gift | 49.7% | 40,000 | 120,500 | 10 Mar 2026 | by Trust | ||
| Asit Parikh | PHAT | Common Stock | Gift | -79.2% | -40,000 | 10,500 | 10 Mar 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -2.19% | -1,378 | 61,480 | 27 Feb 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Award | 33.6% | 15,790 | 62,858 | 27 Feb 2026 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Tax liability | -1.7% | -1,535 | 88,660 | 10 Feb 2026 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Award | 3.99% | 3,461 | 90,195 | 10 Feb 2026 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -1.65% | -6,277 | 373,315 | 10 Feb 2026 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Award | 3.37% | 12,362 | 379,592 | 10 Feb 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Gift | 80,500 | 80,500 | 23 Jan 2026 | by Trust | |||
| Asit Parikh | PHAT | Common Stock | Gift | -61.4% | -80,500 | 50,500 | 23 Jan 2026 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -1.62% | -776 | 47,068 | 21 Jan 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock | Options Exercise | 7.16% | 8,750 | 131,000 | 13 Jan 2026 | Direct | ||
| Asit Parikh | PHAT | Common Stock (Right to Buy) | Options Exercise | -100% | -8,750 | 0 | 13 Jan 2026 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Award | 220.6% | 251,034 | 364,820 | 02 Jan 2026 | Direct | ||
| Steven L. Basta | PHAT | Stock Option (Right to Buy) | Award | 226,156 | 221,156 | 02 Jan 2026 | Direct | |||
| Anne Marie Cook | PHAT | Common Stock | Award | 779.4% | 75,345 | 85,012 | 02 Jan 2026 | Direct | ||
| Anne Marie Cook | PHAT | Stock Option (Right to Buy) | Award | 67,878 | 67,878 | 02 Jan 2026 | Direct | |||
| Sanjeev Narula | PHAT | Common Stock | Award | 57.4% | 82,715 | 226,715 | 02 Jan 2026 | Direct | ||
| Sanjeev Narula | PHAT | Stock Option (Right to Buy) | Award | 42,848 | 42,848 | 02 Jan 2026 | Direct | |||
| Asit Parikh | PHAT | Common Stock | Options Exercise | 7.71% | 8,750 | 122,250 | 19 Dec 2025 | Direct | ||
| Asit Parikh | PHAT | Common Stock (Right to Buy) | Options Exercise | -50% | -8,750 | 8,750 | 19 Dec 2025 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Tax liability | -0.48% | -230 | 47,844 | 18 Dec 2025 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Tax liability | -44.4% | -7,703 | 9,667 | 17 Dec 2025 | Direct | ||
| Anne Marie Cook | PHAT | Common Stock | Award | 17,370 | 17,370 | 17 Dec 2025 | Direct | |||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -21.7% | -31,502 | 113,786 | 17 Dec 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Award | 74.5% | 62,038 | 145,288 | 17 Dec 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Tax liability | -36.8% | -48,375 | 83,250 | 28 Nov 2025 | Direct | ||
| Steven L. Basta | PHAT | Common Stock | Options Exercise | 216.2% | 90,000 | 131,625 | 28 Nov 2025 | Direct | ||
| Steven L. Basta | PHAT | Performance Shares | Options Exercise | -33.3% | -90,000 | 180,000 | 28 Nov 2025 | Direct | ||
| Robert Charles Breedlove | PHAT | Common Stock | Sale | -1.09% | -$7,079 | $13.51 | -524 | 47,407 | 03 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.